Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Quest Diagnostics, Genalyte

Premium

Quest Diagnostics this week released two tests for the diagnosis of rheumatoid arthritis based on the 14-3-3eta protein.

One test consists 14-3-3eta protein alone, while the other includes this protein along with established RA markers cyclic citrullinated peptide antibodies and rheumatoid factor. The tests, are intended for the diagnosis of RA, and early diagnosis of the disease in particular, the company said.

Quest licensed US rights to the 14-3-3eta protein from Canadian biotech firm Augurex (see related story this issue).


Genalyte this week released its MT-ADA anti-drug antibody immunogenicity assay for drug development.

The assay is intended for detecting unwanted immune responses to drugs by measuring the presence of anti-drug antibodies. The test allows for simultaneous detection of eight antibody classes and can be used for both mouse and human samples, the company said.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.